By Kenneth Posted 14 October 2019 In Venture CapitalForbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing2019-10-142019-10-16http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.